Laboratories all over the world conduct research aimed at developing novel strategies to treat cancer. The approaches include innovative chemotherapy and prodrug agents, therapeutic antibodies, immunotherapies, nanoparticle-based approaches, targeted ultrasound, photodynamic therapy, radiation therapy, biological therapies, and combinations thereof. Recently, live vectors for the treatment and delivery of anticancer agents to tumors have gained considerable interest, primarily because of the ability of a number of microorganisms (bacteria and viruses) to naturally colonize and specifically replicate in tumors. Their natural tropism for cancers makes certain microorganisms ideal for delivery of either conventional or novel therapeutic modalities, but potentially spares patients the adverse effects associated with toxicity to healthy cells. Secondarily, the infection of tumors with microorganisms can elicit strong antitumor immune activation, resulting also in the specific destruction of the malignant cells. At the end of the 19th century, Busch and Fehleisen in Germany and Coley in the United States established the scientific basis for biological therapies by purposefully administering infectious bacteria to cancer patients (1) (2) (3) . Later, in the middle of the 20th century, interest in tumor-colonizing microorganisms resumed when genetic engineering established the methods by which the genomes of bacteria and viruses could be specifically modified, providing direct control over virulence, attenuation, and the expression of heterologous genes, permitting, for example, the optical imaging of infecting microorganisms (4, 5) .
Quispe-Tintaya et al., as reported in PNAS, have taken a major next step in this emerging field of biological therapy (6) . The authors report a unique combinatorial strategy against cancer using radiolabeled antibodies bound to tumor-colonizing bacteria, thereby enhancing therapeutic efficacy in a model of metastatic pancreatic cancer in mice. Quispe-Tintaya et al. use a virulenceattenuated strain of the food-borne pathogen Listeria monocytogenes, which is capable of replicating both extracellularly and also in the cytosol of infected mammalian cells. Previously in 1975, L. mononcytogenes was first tested as an antitumor treatment by injecting the bacterium intratumorally in a fibrosarcoma model in guinea pigs (7) . Subsequently, listeriae were used for induction of antitumoral immunresponses. In particular, Paterson and colleagues used engineered L. monocytogenes strains expressing heterologous tumor antigens for immunotherapy against different human cancers (8). The present study differs from the previous work in that it takes advantage of the potential of L. monocytogenes to colonize and replicate in tumors and metastases after systemic administration (5) . In contrast to earlier approaches that combine radiotherapy with bacterial tumor therapy, here 188 Rhenium ( 188 Re)-labeled antibodies were directly linked to the bacterium before injection. Therefore, Quispe-Tintaya et al. (6) injected a single agent (live bacteria with bound antibodies) rather than administering the radiotherapeutic and the bacterial tumor therapy independently.
The combination elicited a strong synergistic effect. Injected alone, the bacterial vector reduced the size of the primary tumors by 20% and the metastatic burden by about 40%. Injection of the 188 Re-labeled antibodies alone had no effect on the tumors or the metastases. However, the injection of 188 Re-labeled Rh (symbolized by red dots)-containing antibodies (gray "Y"-shaped structures) are bound to L. monocytogenes bacteria (brown). The bacteria enter the tumor either directly via capillaries or after infection of MDSCs (green), which migrate to the metastases and primary tumors. Once inside the tumor the bacteria may exist extracellularly, directly infect and replicate in cancer cells (gray), or replicate in MDSCs. Additional cancer cells may be infected via actin-mediated spreading from neighboring infected MDSCs or cancer cells. Although during replication the amount of radiolabeled antibody per bacterium will diminish, reactive oxygen species in infected tumor cells will increase, leading to their further destruction. However, Quispe-Tintaya et al. (6) attributed the major cytocidal effect to 188 Re radiation (red arrow), which leads to DNA damage and cell death, especially in quickly dividing metastatic cancer antibodies bound to L. monocytogenes resulted in reduction of the primary tumor by more than 60%, and remarkably, the number of detectable metastases was reduced by more than 90%. Metastases had greater 188 Re concentrations and the antibodybound bacteria were found to replicate to a greater degree in metastases than the solid tumors. Additionally, Quispe-Tintaya et al. (6) found that myeloid-derived suppressor cells (MDSCs), particularly monocytic MDSCs, were infected by the bacteria.
Quispe-Tintaya et al. (6) suggest the following mechanisms of action for the unique therapeutic strategy (Fig. 1 ): Based on their results and previous publications (9-11), the authors hypothesize that direct cytotoxicity caused by 188 Re radiation, especially in highly proliferating metastases, resulted in cancer cell death. Additionally, elevated concentrations of reactive oxygen in infected cancer cells resulted cell destruction. The authors further suggest that tumor-infiltrating MDSCs, serving as in vivo transporters of the 188 Re antibody-laden bacteria, serve to mediate the process. Notably, cytotoxic T cells and NK cells were shown to play only a minor role in the observed effects. It is expected that the combined radiation and biotherapy would result in prolonged survival of treated animals, although these data are not presented. Important from a clinical perspective, no pathological effects on healthy tissues were observed and liver functions were not altered as a consequence of treatment, despite the greater levels of radioactivity present in liver and kidneys compared with other organs and even metastases.
The results of this study will undoubtedly stimulate future experiments to further characterize and improve the reported effects. As discussed by Quispe-Tintaya et al. (6), L. monocytogenes could be coupled to (radiolabeled) tumor-specific antibodies to enhance tumor selectivity of the bacteria, thus positively influencing the therapeutic activity. Virulence-attenuated auxotrophic mutants that still possess all of their virulence genes (12, 13) 188 Re has a short half-life relative to other β-emitting isotopes, its relatively high mean emission path length of about 2.5 mm may have limited utility treating smaller metastases and may result in increased bystander damage to adjacent healthy tissues. Finally, combining the radiotherapy and biotherapy approach with the expression of radiosensitizing molecules and proteins or the delivery of prodrug-converting enzymes (14) to enhance the antitumor effect could be of value. Moreoever, active bacterial uptake/binding of radioactivity because of the expression of specific transporters/receptors during the colonization process might be another strategy that can be used to enhance biological therapies. It is interesting to speculate whether this strategy could result in similar efficiencies to the presented approach.
Taking these data together, the study by Quispe-Tintaya et al. (6) clearly demonstrates the therapeutic benefit of a strategy combining the tumor targeting and biotherapeutic effects of L. monocytogenes with the cytotoxic effects of 188 Re-labeled antibodies administered as a single agent. Still to be elucidated, however, is the exact mechanism by which this exciting unique combinatorial therapeutic approach works and how it can be potentially improved. The work by Quispe-Tintaya et al. (6) certainly is a major step forward in the search for Paul Ehrlich's "magic bullet" in the war against cancer.
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